Drugs / EX5619
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05335044 | May → Jun 2022 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EX5619 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05335044 ↗ |
| Route | Oral | “QD, PO” NCT05335044 ↗ |